208 - Prevention of Myelosuppression Associated with Concurrent Chemoradiotherapy in Limited Stage Small Cell Lung Cancer

11:25am - 11:35am PT

Room 20/21

Presenter(s)

Chang Liu, PhD - Peking University International Hospital, Beijing,

L. Xinrong; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Purpose/Objective(s):

The objective of this study was to assess the effectiveness and safety of trilaciclib in the treatment of limited-stage small cell lung cancer (LS-SCLC) with concurrent chemoradiotherapy associated with myelosuppression, aiming to reduce the incidence of myelosuppression for patients.

Materials/Methods:

This study is an open, single-arm phase II clinical study. All patients with LS-SCLC who received platinum-doublet chemotherapy and concurrent radiotherapy after 1-2 cycles of induction chemotherapy, trilaciclib was given intravenously 4 hours before chemotherapy. Primary endpoint was the incidence of grade 3 severe neutropenia (SN), Secondary endpoins included incidence of grade 3/4 hematological toxicity, use of antibiotics, transfusion, and hematopoietic growth factors, and safety.

Results:

A total of 18 patients were enrolled for efficacy and safety analysis. Within 14 days of the first chemotherapy cycle with trilaciclib during radiotherapy. The incidence of Grade 3 severe neutropenia was 11.1% (2/18). The incidence of grade 3 hematologic adverse events was 27.8% (5/18), the incidence of grade 1/2 hematologic adverse events was 66.7% (12/18), and no grade 4 hematologic adverse events occurred. The incidence of grade 3 leukopenia was 22.2% (4/18), and the incidence of grade 3 thrombocytopenia was 5.5% (1/18). The incidence of grade 2 anemia was 11.1% (2/18), grade 2 thrombocytopenia was 16.7% (3/18), grade 2 leukopenia was 33.3% (6/18), and grade 2 neutropenia was 27.8% (5/18). During the treatment period, 83.3% of patients had any Grade 1 adverse events (AEs), among which Grade 3 AE occurred in 27.8%. No AEs caused drug discontinuation and radiotherapy interruption, and no serious AE or death occurred. AE associated with trilaciclib included injection site reactions (22.2%), phlebitis/thrombophlebitis (5.5%).

Conclusion:

The use of trilaciclib in LS-SCLC patients receiving concurrent chemoracidotherapy reduces the occurrence of SN, has a multiline myelosuppression protection, and does not increase the risk of chemotherapy.